Research programme: cannabinoid based anticancer therapeutics - Pascal Biosciences
Alternative Names: PAS-403; ST 403; ST compounds - Pascal BiosciencesLatest Information Update: 28 Nov 2022
At a glance
- Originator University of Washington
- Developer Pascal Biosciences; University of Montana; University of Washington
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain metastases; Glioblastoma
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Brain metastases in USA
- 28 Nov 2022 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 30 Oct 2018 Pascal Biosciences plans a clinical trial of ST 403 (PAS 403) for Brain metastases and Glioblastoma in 2019